INTRODUCTION
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) is rising in the United States and other developed countries, and this is driven by human papillomavirus (HPV). [1] [2] [3] The incidence of OPSCC is increasing most dramatically among younger age groups, 4 and this is consistent with the recognized demographics of the disease. Past research has shown that patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma (HPV-OPSCC) have a lower median age at diagnosis than patients with HPV-negative OPSCC. 5, 6 Indeed, earlier studies showed that the median age at OPSCC diagnosis decreased during 4 and 1977-2012, 7 likely because of the growing proportion of HPV-OPSCCs. However, a recent population-based study reported an increase in OPSCC incidence among adults 65 years or older in the United States between 2000 to 2012, and there was a concomitant decrease in nonoropharyngeal head and neck cancer among adults of the same age. 8 This suggests that the increase in OPSCC incidence among older adults may be driven by HPV, although this has not been well studied.
An HPV-positive tumor status is a well-established marker of an improved prognosis for OPSCC at both the time of diagnosis and disease recurrence. [9] [10] [11] [12] [13] Notably, age is an important marker of prognosis for most cancers, including OPSCC. 13, 14 Therefore, we were interested in exploring whether the prevalence of HPV-positive tumors is increasing and whether the prognostic advantage of HPV is retained among older patients.
MATERIALS AND METHODS
This was a retrospective analysis of squamous cell carcinomas of the oropharynx diagnosed between 1995 and 2013 at 2 National Comprehensive Cancer Network-designated Comprehensive Cancer Centers: the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital (Baltimore, Maryland) and the University of California San Francisco Helen Diller Family Comprehensive Cancer Center (San Francisco, California), in an institutional review board approved study. This analysis focuses on a subset of head and neck squamous cell carcinoma cases previously described 13 in a study enriched for female and nonwhite participants. Medical record abstraction was performed to summarize clinical variables, including age, sex, race/ethnicity, and ever tobacco use, and to confirm tumor sites and American Joint Committee on Cancer (AJCC) tumor and nodal stages (7th edition). 15 
Testing Methods
Tumor testing was performed centrally in 2014 and 2015 and was interpreted by a single pathologist (W.H.W.).
Sampling and testing methods have been previously described. 16 p16 immunohistochemistry was performed (MTM Laboratories, Heidelberg, Germany), and p16 expression was considered positive if a 70% strong and diffuse nuclear and cytoplasmic staining pattern was observed. In situ hybridization (ISH) was performed for HPV-16 DNA (GenPoint; Dako, Carpinteria, California). In cases that were p16-positive and HPV-16 ISH-negative, either high-risk HPV DNA (Dako GenPoint) or HPV E6/ E7 RNA ISH (RNAScope; Advanced Cell Diagnostics, Hayward, California) was performed. Because p16 is now considered to be a surrogate marker for an HPV-positive tumor status 6, 17 and will be used to establish the HPV tumor status in the AJCC Cancer Staging Manual, 8th edition, 18 the primary tumor outcome was defined with the p16 status. Secondary analyses were also conducted with the ISH tumor status, as previously described. 13 
Statistical Analysis
Descriptive statistics were reported as numbers and percentages or as medians and interquartile ranges (IQRs). (Table 1) .
Trends in the Prevalence of HPV-Positive Tumors Among OPSCCs
Among all age groups, including older adults, the proportion of p16-positive tumors increased over the study period (Fig. 1) Trends in the mean age at diagnosis over time were also explored (Fig. 2) . Among patients with p16-positive OPSCC, the age at diagnosis decreased by 3 years of age for each calendar year during 1995-2000 (b 5 -3.0, P 5 .07). A nonsignificant increase in age (b 5 1.2, P 5 .30) during 2001-2006 was followed by a dramatic and significant increase in the mean age of 2 years for every calendar year (b5 2.0, P 5 .01) during 2007-2013 (Fig. 2A) . The age at diagnosis of patients with p16-negative OPSCC remained stable over time (P values > .30; Fig. 2B ). Similar trends were observed when the ISH tumor status was considered. 
Survival Differences by HPV Tumor Status and Age
The median follow-up time was 3.5 years (IQR, 1.3-6.9 years). According to the Kaplan-Meier analysis, patients with p16-positive OPSCC had improved OS in comparison with p16-negative patients in all age groups (5-year OS, 77% vs 40%; P < .001). OS was better for p16-positive patients in every age group, including younger patients (5-year OS, 77% vs 42%; HR, 0.43; 95% confidence interval [CI], 0.22-0.83; P 5 .01), middle-aged patients (5-year OS, 87% vs 40%; HR, 0.18; 95% CI, 0.08-0.42; P < .001), and older patients (5-year OS, 59% vs 34%; HR, 0.45; 95% CI, 0.23-0.89; P 5 .02; Fig. 3 and Table 2 ). After we had controlled for other factors, p16 conferred substantially improved survival within the entire study population (adjusted hazard ratio [aHR], 0.31; 95% CI, 0.19-0.51; P < .001) and among younger (aHR, 0.31; 95% CI, 0.13-0.73; P 5 .01) and middleaged patients (aHR, 0.09; 95% CI, 0.01-0.60; P 5 .01). Among older adults, a p16-positive tumor status was nonsignificantly associated with improved survival (aHR, 0.46; 95% CI, 0.17-1.27; P 5 .14). The survival benefit of the p16 tumor status was possibly lower in the older age group, but this difference was not statistically significant (P interaction age and p16 5 .24). Exploring only p16-negative OPSCC, we found that OS at 5 years was similar in the younger (42%; 95% CI, 24%-60%), middle-aged (40%; 95% CI, 22%-58%), and older adults (34%; 95% CI, 14%-56%; P 5 .34). Findings were similar when the ISH tumor status was considered.
DISCUSSION
This is the first study to demonstrate that the observed rise in OPSCC among older adults is driven by an increased prevalence of p16-positive tumors (HPV from here forward), and this indicates that HPV-OPSCC is no longer a disease of young individuals. Notably, the age at diagnosis of patients with HPV-OPSCC has increased in recent years, and HPV remains a biomarker of improved prognosis among older patients.
The younger median age (53 years) at diagnosis for HPV-OPSCC in the earliest calendar period, 1995-2000, is consistent with the average age reported in the literature. 5, 6 This has led to the conclusion that patients with HPV-OPSCC are younger than their HPV-negative counterparts. Several earlier epidemiologic studies reported a dramatic increase in the incidence of OPSCC among younger age groups in comparison with middle and older age groups across time periods, including 1973-1995, 19 1974-2003, 14 and 1983-2002. 1 This trend appeared to arise from a combination of the younger age at diagnosis for HPV-OPSCC (with respect to HPV-negative OPSCC) and the increasing incidence of HPV-OPSCC overall. According to Surveillance, Epidemiology, and End Results data from 1973 to 2004, the median age at diagnosis for OPSCC declined by 0.5 years per decade (P < .001). 4 Similar findings have been reported in some other countries. For example, in Denmark, the average age at diagnosis for patients with OPSCC decreased over time during 1977-2012. 7 More recent analyses of Surveillance, Epidemiology, and End Results data, however, have reported an increase in OPSCC incidence in older adults as well. 8, 20 Although the incidence in this age group had been stable for 25 years (1975-2000) , there was a significant increase in the incidence of OPSCC among older adults in the United States between 2000 and 2012. 8 Consistent with these incidence trends, the increase in age observed in the current analysis appears to be driven by the most recent calendar period (2007) (2008) (2009) (2010) (2011) (2012) (2013) . Although it has been recently hypothesized that the prevalence of HPV-related tumors has increased among older adults, 8 this was not established before the current study. The current analysis, using gold-standard , overall survival for p16-positive (n 5 60) and p16-negative patients (n 5 38) was 82% and 66%, respectively, at 2 years and 77% and 42%, respectively, at 5 years. (B) For middle-aged patients (age, 55-64 years), overall survival for p16-positive (n 5 49) and p16-negative patients (n 5 34) was 92% and 60%, respectively, at 2 years and 87% and 40%, respectively, at 5 years. (C) For older patients (age, 65 years), overall survival for p16-positive (n 5 35) and p16-negative patients (n 5 23) was 88% and 69%, respectively, at 2 years and 59% and 34%, respectively, at 5 years. tumor detection methods and centralized testing, demonstrates that an increasing proportion of OPSCCs are caused by HPV in all age groups, including older adults. This suggests that the recent increase in OPSCC incidence in older adults is indeed due to HPV. This is the first study to identify that the median age of patients with HPV-OPSCC is now increasing. This finding presents a paradigm shift: HPV-OPSCC is no longer a disease solely of younger patients but is one that affects adults across the age spectrum. Previous literature has focused on the distinct demographic characteristics of patients with HPV-OPSCC. Our data, in the context of recent reports regarding incidence trends, suggest that the clinical presentation of OPSCC is evolving. Reasons for the increase in the incidence of OPSCC among older patients and the increase in the prevalence of HPV-positive tumors among older (and younger) patients were not explored in the current analysis but may potentially be explained by a cohort effect.
Consistent with prior literature, an HPV-positive tumor status was an independent marker of improved OS. 13 After stratification by age group, an HPV-positive tumor status remained associated with a reduction in the risk of death for younger, middle-aged, and older age groups. The magnitude of the survival benefit conferred by an HPV-positive tumor status appears to possibly be reduced for older patients in comparison with either younger or middle-aged patients. The magnitude of the reduction in the risk of death conferred by an HPV-positive tumor status among older patients in this study (aHR, 0.46) was similar to that observed in a recent Princess Margaret Cancer Centre analysis restricted to patients older than 70 years (HR, 0.58). 21 This finding may reflect competing risks for mortality among older patients. Because information on disease-specific survival was not available for all patients, this outcome could not be explored in this analysis but should be a part of future study designs.
The observation that survival differences may be attenuated in older patients is of clinical importance. Treatment de-intensification is the focus of current clinical trials in an attempt to reduce the long-term morbidity for younger and middle-aged OPSCC patients, who are expected to have long-term survival. 22 However, an acknowledgment of the worse OS of older patients versus younger patients and the potentially reduced prognostic benefit of HPV positivity raises the question whether such an approach should be adopted for older patients.
Toxicities of multimodality treatment are thought to be increased among older patients. 23 It is suspected that older patients have a lower threshold for toxicities and a resultant narrower therapeutic ratio for treatment, and indeed this demographic tends to receive less treatment. 24, 25 However, patients older than 65 years are underrepresented in clinical trials. 26 A recent meta-analysis showed that the few studies examining treatment outcomes by age had mixed findings. The majority were unable to show a significant difference in OS with each treatment modality by chronological age, yet there was a substantive correlation with the patient functional status instead. 27 Older adults require more supportive care 28 and have unique psychosocial experiences. 29 They may potentially have distinct goals of treatment in the context of aging, a greater number of comorbidities, 30, 31 and a shorter posttreatment life expectancy. Therefore, understanding the goals of treatment in this growing population emerges as an important consideration. Additional prospective trials are needed to delineate the response to therapy and optimum treatment paradigms for older adults with HPV-OPSCC.
This study has several benefits and limitations. The current analysis provides a large sample from 2 cancer centers spanning 18 years with centralized testing. Limitations include the retrospective nature, the potentially decreased ability to generalize trends at these centers to the US population, and the absence of treatment data and disease-specific survival. We acknowledge that the competing risks of mortality for older patients are greater than those for younger patients; thus, a limitation of this analysis is that conclusions are based on OS.
In summary, HPV-OPSCC should no longer be considered a disease associated with younger patients. The age at diagnosis for patients with HPV-OPSCC has increased over recent years, whereas that for patients with HPV-negative OPSCC has remained stable. This reflects the rise in HPV-OPSCC in all age groups, including older adults, over time and establishes a basis for additional population-based studies. Lastly, the survival benefit conferred by an HPV-positive tumor status, as determined by p16 and ISH, appears to endure with increasing age at diagnosis, although it is possible that this benefit may attenuate with increasing age. Further investigation is needed to assess this possible trend. We emphasize the importance of including older patients in clinical trials and anticipating the needs unique to this new and growing older demographic. Our results should inform the allocation of health care spending as well as future research directions.
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